Cytodyn Inc (CYDY)

[spiritof76]

Dear Sir,
I did post the research, did you take time to read it?

"Remdesivir and Leronlimab where tested in rigorous double blind critical,moderate,mild or whatever it would not be close listen to what Dr.Patterson says about the drugs our drug calms the cytokines storm reduces viral load and kills the virus while Remdesivir does none of that go and research something before it’s posted to be sure it has credibility" Per your statement.

May you please provide a link to support this above statement? Actual study results to my knowledge are not available to anyone else but you regarding leronlimab Severe study data.

Either way, CYDY is a company with a 2.5 Billion dollar market cap. They have only one future product, Leronlimab. They are marketing it for covid 19 per forward looking statements. One study is completed and one is on going for Covid 19. They have another in Mexico of 25 patients not yet started. I strongly feel it is the best interest of share holders to not wait around for results. Another study should be designed and started for Covid 19 therapy. Only about 1-2% of all covid 19 will be of severe status. I am amiss as to why share holders don't want to go after the other 98%. A simple out patient study, (they are cheaper), to assess effectiveness and cost savings for Leronlimab Vs Placebo in Sub Q injections as out patients. Primary out come measures time to reduction in symptoms and recovery. Secondary measures decreased medical costs through a reduction in hospital admissions and decreased transmittance of covid 19 among house hold members. A phase 2 study of 75 (now 86) mild to moderate covid 19 patients would require a follow up study, even if approval by the FDA is reached.

Even if you don't not support my future studies of Covid 19 and only want to focus on Severe patients with covid 19 do you not feel we should start some other studies. After all 2.5 billion market cap with only one possible product, you want to get the most return on that product.

If you would like to read the data I am referring to in regards to remdesivir here is the link:

https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/gilead-presents-additional-data-on-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19